Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)
Close on Nov 18, 2026Market cap $10.34BP/E –Yield –
Kymera Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Kymera Therapeutics's revenue for the twelve months ending Sep 30, 2026 was $102.24M, up 133.8% year over year. For fiscal 2025 it was $39.21M, down 16.7% from the year before. The highest annual figure on record is $78.59M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.21M | -16.7% |
| FY2024 | Dec 31, 2024 | $47.07M | -40.1% |
| FY2023 | Dec 31, 2023 | $78.59M | +67.8% |
| FY2022 | Dec 31, 2022 | $46.83M | -35.7% |
| FY2021 | Dec 31, 2021 | $72.83M | +114.0% |
| FY2020 | Dec 31, 2020 | $34.03M | +1060.0% |
| FY2019 | Dec 31, 2019 | $2.93M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0 | -100.0% |
| Q2 FY2026 | Jun 30, 2026 | $65.00M | +466.4% |
| Q1 FY2026 | Mar 31, 2026 | $34.37M | +55.5% |
| Q4 FY2025 | Dec 31, 2025 | $2.87M | -61.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.76M | -26.1% |
| Q2 FY2025 | Jun 30, 2025 | $11.48M | -55.3% |
| Q1 FY2025 | Mar 31, 2025 | $22.10M | +114.8% |
| Q4 FY2024 | Dec 31, 2024 | $7.39M | -84.6% |
| Q3 FY2024 | Sep 30, 2024 | $3.74M | -20.9% |
| Q2 FY2024 | Jun 30, 2024 | $25.65M | +55.3% |
| Q1 FY2024 | Mar 31, 2024 | $10.29M | +8.7% |
| Q4 FY2023 | Dec 31, 2023 | $47.89M | +196.7% |
| Q3 FY2023 | Sep 30, 2023 | $4.73M | -50.5% |
| Q2 FY2023 | Jun 30, 2023 | $16.51M | +43.4% |
| Q1 FY2023 | Mar 31, 2023 | $9.47M | -1.6% |
| Q4 FY2022 | Dec 31, 2022 | $16.14M | +5.7% |
| Q3 FY2022 | Sep 30, 2022 | $9.55M | -53.0% |
| Q2 FY2022 | Jun 30, 2022 | $11.51M | -37.8% |
| Q1 FY2022 | Mar 31, 2022 | $9.62M | -48.6% |
| Q4 FY2021 | Dec 31, 2021 | $15.28M | +19.5% |
| Q3 FY2021 | Sep 30, 2021 | $20.34M | +39.9% |
| Q2 FY2021 | Jun 30, 2021 | $18.52M | +463.2% |
| Q1 FY2021 | Mar 31, 2021 | $18.70M | +445.6% |
| Q4 FY2020 | Dec 31, 2020 | $12.79M | +597.5% |
| Q3 FY2020 | Sep 30, 2020 | $14.53M | +1429.8% |
| Q2 FY2020 | Jun 30, 2020 | $3.29M | – |
| Q1 FY2020 | Mar 31, 2020 | $3.43M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.83M | – |
| Q3 FY2019 | Sep 30, 2019 | $950.00K | – |
See a number that looks wrong?